Who
Pratik Shah
Director
Company insider
Files Form 4 as: Director and 10% owner, ARS Pharmaceuticals; President, CEO and Chairperson, Design Therapeutics; Director, Synthorx; President and CEO, Auspex Pharmaceuticals; Director, Ocera Therapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 2
- Sells
- 0
- Bought
- $600K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 30 Aug 2013
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 12 Nov 2025filed 14 Nov 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —250,000 at $0.00 | filing |
| 12 Nov 2025filed 14 Nov 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —200,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —1,132,900 at $0.00 | filing |
| 7 Jun 2024filed 7 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —1,332,950 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code J | —2,665,800 | filing |
| 4 Jun 2024filed 6 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —1,332,900 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —1,332,900 at $0.00 | filing |
| 1 Sep 2023filed 5 Sep 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,050,000 at $0.00 | filing |
| 1 Sep 2023filed 5 Sep 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 1 Sep 2023filed 5 Sep 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.